Quarterly Results, Awards, Positive Trial Data, and New Board Members Support Optimism for Healthcare - Research Report on

Quarterly Results, Awards, Positive Trial Data, and New Board Members Support
 Optimism for Healthcare - Research Report on Allergan, Cubist, Forest, Isis
                         Pharmaceuticals, and Amarin

PR Newswire

NEW YORK, July 5, 2013

NEW YORK, July 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting
Allergan Inc. (NYSE: AGN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Forest
Laboratories Inc. (NYSE: FRX), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and
Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Allergan Inc. Research Report

On June 28, 2013, Allergan Inc. (Allergan) announced that the Company will
release its Q2 2013 results on Wednesday, July 31, 2013. The release will be
discussed by David Pyott, Chairman of the Board and Chief Executive Officer,
along with Jeff Edwards, Executive Vice President of Finance and Business
Development and Chief Financial Officer of Allergan. The Company further
informed that investors may access a live webcast of the release at Allergan's
website, beginning at 8:00 a.m. PT. A replay of the same will also be
available at the Company's website for one week after the conclusion of the
live call. The Full Research Report on Allergan Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/1c25_AGN]


Cubist Pharmaceuticals Inc. Research Report

On June 28, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that Michael
W. Bonney, CEO of Cubist, was named among the winners of the Ernst & Young
Entrepreneur Of The Year 2013 Award New England, in the Life Sciences
category. Bonney commented, "I am honored to be recognized as one of the Ernst
& Young Entrepreneur Of The Year Award New England winners. It is truly
humbling to be in the company of such great leaders across the region." He
continued, "The award is a reflection of all of Cubist's employees who bring
passion and dedication to our mission of transforming patients' lives. The
award also recognizes Cubist's dedication to the New England area, supporting
local communities through middle and high school science, technology,
engineering and math (STEM) education programs. Our support of STEM education
is an integral part of Cubist's corporate culture of which I am personally
proud." The Full Research Report on Cubist Pharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Forest Laboratories Inc. Research Report

On June 27, 2013, Forest Laboratories Inc. (Forest) reported positive top line
results from its eight-week pivotal Phase III clinical trial, conducted to
evaluate the efficacy and safety of investigational fixed dose combination
(FDC) of nebivolol and valsartan for the treatment of hypertension. Marco
Taglietti, MD, Senior Vice President of Research and Development and President
at Forest Research Institute, stated, "These Phase III results in patients
with Stage 1 or Stage 2 hypertension are exciting and demonstrate the
potential benefits of this novel FDC -- a first-in-class beta blocker/ARB
combination." Taglietti added, "We are very pleased with these results which
demonstrate the efficacy and safety profile of this combination and support
the potential use of the nebivolol/valsartan FDC as a new treatment option for
patients with hypertension who need dual therapy to reach their blood pressure
goals." Forest also reported that based on the positive outcome of the trial,
the Company intends to submit a regulatory filing with the US Food and Drug
Administration during Q1 2014. The Full Research Report on Forest Laboratories
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


Isis Pharmaceuticals, Inc. Research Report

On June 25, 2013, Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) announced
that Breaux Castleman has joined its Board of Directors. Stanley T. Crooke,
M.D., Ph.D., Chairman and CEO of Isis said, "We are very pleased to have
Breaux join our Board. Breaux has held executive positions in some of the
nation's leading managed care provider organizations and has been a pioneer in
creating innovative solutions to deliver value in the healthcare sector."
Crooke continued, "Breaux' leadership and sound business judgment will be
valuable to Isis as we continue to successfully implement our business
strategy and evaluate opportunities within our pipeline to retain some of our
drugs to later stages in development; thereby retaining a larger portion of
the commercial upside of these drugs." The Full Research Report on Isis
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Amarin Corporation plc Research Report

On June 21, 2013, Amarin Corporation plc (Amarin) announced positive results
from the Phase I clinical trial that compared the bioavailability of
components from a fixed-dose combination of Vascepa (icosapent ethyl) and
rosuvastatin (AMR-102), to concomitant administration of the two agents
independently, and to rosuvastatin alone. Joseph Zakrzewski, Chairman and CEO
of Amarin, stated, "The encouraging results of this pharmacokinetic study
represent a crucial step in the plan to solidify a fixed-dose formulation of
Vascepa capsules with statins." Amarin reported that the results of
multiple-dose study to assess the AMR-102 in 48 volunteers proved promising
and was well-tolerated. The Company also reported that under its ANCHOR trial,
Vascepa showed robust reductions in TGs and a broad range of other lipid
parameters on top of optimized statin therapy, including atorvastatin,
simvastatin, and rosuvastatin. Zakrzewski continued, "These claims from the
ANCHOR fixed-dose formulation, along with other recently allowed and granted
patents that cover a fixed dose combination product from the MARINE trial give
Amarin a strong IP position for AMR-102." The Full Research Report on Amarin
Corporation plc - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.